Gabapentinoids linked to increased risk for severe exacerbation in COPD
Jan 16, 2024
Compared with matched nonusers, gabapentinoid users have an increased risk across indications of epilepsy, neuropathic pain and other chronic pain.
Antibiotics not helpful for cough due to lower respiratory tract infection
Apr 25, 2024
Despite patient beliefs, no effect was seen on the severity or duration of the cough.
COVID-19 meds like Paxlovid will soon have big price tags
Oct 30, 2023
The pills still will be available at no cost until those bought earlier by the federal government run out.
Risk for dementia reduced in association with antihypertensive use
Sep 13, 2023
An individual patient data meta-analysis shows increased risk for dementia for those with untreated hypertension.
Paxlovid not helpful for reducing most post-COVID-19 conditions
Oct 31, 2023
No differences were seen in most post-COVID-19 conditions examined individually or by organ system, apart from a lower combined risk for venous thromboembolism and pulmonary embolism.
Use of acid-suppression therapy linked to migraine, severe headache
Apr 26, 2024
Adjusted odds ratios of 1.70, 1.40 and 1.30 were seen for proton pump inhibitors, H2 receptor antagonists and generic antacids, respectively.
Four in 10 US adults say they know someone who died from drug overdose
Feb 28, 2024
One-third of those say their lives were disrupted by the overdose death.
Risk for adverse outcomes increased with antipsychotic use in dementia
Apr 19, 2024
Risks increased for stroke, venous thromboembolism, myocardial infarction, heart failure, fracture, pneumonia and acute kidney injury.
One-quarter of older advanced cancer patients taking eight or more drugs
Mar 20, 2023
Polypharmacy was tied to an increased risk for adverse treatment outcomes, such as toxicity and early treatment discontinuation.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.